【佳学基因靶向药物基因检测】BRAF V600E 突变对神经胶质瘤的影响：分子因素、预后价值和治疗进展

基因肿瘤检测哪家医院最好解析

阅读的药物化治疗及药物选择发现《Front Oncol》在 2023 Jan 4;12:1067252.发表了一篇题目为《Glioblastoma: Emerging Treatments and Novel Trial Designs》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Vincenzo Di Nunno, Lidia Gatto, Alicia Tosoni, Stefania Bartolini, Enrico Franceschi等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤基因检测及靶向药物治疗研究关键词：

布拉夫, MAPK-甲乙酮,达拉非尼,恩科非尼,胶质母细胞瘤;胶质瘤;曲美替尼,维罗非尼。

肿瘤治疗检测基因临床应用结果

神经胶质瘤是分子异质性脑肿瘤，是任何癌症导致生命损失最多年的原因。高级别胶质瘤预后较差，尽管采用包括手术、放疗和化疗在内的多模式治疗，但仍表现出高复发率。需要基于生物标志物评估和 BRAF 的精确医学的新治疗方法，BRAF 是 MAPK 信号通路的关键调节因子，影响细胞分化、增殖、迁移和促肿瘤发生活性，正在成为一个有前途的分子靶点。 V600E 是胶质瘤中最常见的 BRAF 改变，尤其是在儿童低级别星形细胞瘤、多形性黄色星形细胞瘤、乳头状颅咽管瘤、上皮样胶质母细胞瘤和神经节胶质瘤中。 BRAF 靶向治疗在神经胶质瘤中的可能应用正在不断增长，并且有初步证据表明 BRAF 抑制剂在携带 BRAF V600E 突变的肿瘤中获得了延长的疾病控制。将靶向治疗引入治疗算法的可能性代表了 BRAF V600E 突变复发性高级别和低级别神经胶质瘤患者的范式转变，临床实践中应考虑 BRAF 常规检测。本综述的重点是总结 BRAF 在神经胶质瘤亚型中的分子图谱和 BRAF V600E 突变肿瘤的新治疗策略。 MAPK-甲乙酮；达拉非尼；恩科非尼；胶质母细胞瘤;胶质瘤;曲美替尼；维罗非尼。

肿瘤发生与革命国际数据库描述：

Gliomas are molecularly heterogeneous brain tumors responsible for the most years of life lost by any cancer. High-grade gliomas have a poor prognosis and despite multimodal treatment including surgery, radiotherapy, and chemotherapy, exhibit a high recurrence rate. There is a need for new therapeutic approaches based on precision medicine informed by biomarker assessment and BRAF, a key regulator of MAPK signaling pathway, influencing cell differentiation, proliferation, migration and pro-tumorigenic activity, is emerging as a promising molecular target. V600E, is the most frequent BRAF alteration in gliomas, especially in pediatric low-grade astrocytomas, pleomorphic xanthoastrocytoma, papillary craniopharyngioma, epithelioid glioblastoma and ganglioglioma. The possible application of BRAF-targeted therapy in gliomas is continuously growing and there is preliminary evidence of prolonged disease control obtained by BRAF inhibitors in tumors harboring BRAF V600E mutation. The possibility of introducing targeted therapies into the treatment algorithm represents a paradigm shift for patients with BRAF V600E mutant recurrent high-grade and low-grade glioma and BRAF routine testing should be considered in clinical practice. The focus of this review is to summarize the molecular landscape of BRAF across glioma subtypes and the novel therapeutic strategies for BRAF V600E mutated tumors.Keywords: BRAF; MAPK-MEK; dabrafenib; encorafenib; glioblastoma; glioma; trametinib; vemurafenib.